Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Mouse GALC ELISA Kit (AC3028)
Cat.#: ASET-1617
Specifications
Description Mouse GALC ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of mouse GALC concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Mouse Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 9.71 ng/L Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 150-2400 ng/L Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1261 Rat AKR7A2 ELISA Kit (AC2672) Quantitative inquiry ASET-2010 Human SEMA3D ELISA Kit (AC3421) Quantitative inquiry ASET-1155 Human SOX9 ELISA Kit (AC2566) Quantitative inquiry ASET-1753 Mouse CD147 ELISA Kit (AC3164) Quantitative inquiry ASET-1250 Human ASIP ELISA Kit (AC2661) Quantitative inquiry ASET-1509 Rat PPAR gamma ELISA Kit (AC2920) Quantitative inquiry ASET-1163 Human Ephrin B1 ELISA Kit (AC2574) Quantitative inquiry ASET-1284 Human alpha B Crystallin ELISA Kit (AC2695) Quantitative inquiry ASET-2078 Rat CDNF ELISA Kit (AC3489) Quantitative inquiry ASET-1545 Mouse Dystrophin ELISA Kit (AC2956) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket